Strengthening the reporting of genetic risk prediction studies: The GRIPS statement

European Journal of Human Genetics

Volumn 19, Issue 8, 2011, Pages 833-836

  Janssens, A Cecile J W ^a   Ioannidis, John P A ^b,c,d,e,f   Van Duijn, Cornelia M ^a   Little, Julian ^g   Khoury, Muin J ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CHECKLIST; CLINICAL PRACTICE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INFORMATION PROCESSING; NEOPLASM; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK FACTOR; WORKSHOP;

DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MODELS, GENETIC;

EID: 79960620808     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.25     Document Type: Article

References (26)

1. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L: The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9: 665-674. (Pubitemid 350287151)
2. Hlatky MA, Greenland P, Arnett DK et al: Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119: 2408-2416.
3. Kyzas PA, Denaxa-Kyza D, Ioannidis JP: Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 2007; 99: 236-243.
4. Kyzas PA, Loizou KT, Ioannidis JP: Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005; 97: 1043-1055. (Pubitemid 41417921)
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK).Nat Clin PractUrol 2005; 2: 416-422. (Pubitemid 43115010)
6. Kyzas PA, Denaxa-Kyza D, Ioannidis JP: Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007; 43: 2559-2579. (Pubitemid 350086938)
7. Tzoulaki I, Liberopoulos G, Ioannidis JP: Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302: 2345-2352.
8. von Elm E, Egger M: The scandal of poor epidemiological research. BMJ 2004; 329: 868-869. (Pubitemid 39422927)
9. Simera I, Moher D, Hoey J, Schulz KF, Altman DG: A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010; 40: 35-53.
10. von Elm E, Altman DG, Egger M, Gøtzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4: e296.
11. Little J, Higgins JP, Ioannidis JP et al: STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 2009; 6: e22.
12. Bossuyt PM, Reitsma JB, Bruns DE et al: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003; 326: 41-44. (Pubitemid 36110721)
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
14. Janssens ACJW, Van Duijn CM: Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 2009; 1: 20.
15. Khoury MJ, Gwinn M, Ioannidis JP: The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 2010; 172: 517-524.
16. Moons KG, Altman DG, Vergouwe Y, Royston P: Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 2009; 338: b606.
17. Khoury MJ, Dorman JS: The human genome epidemiology network. Am J Epidemiol 1998; 148: 1-3. (Pubitemid 28317537)
18. Freedman AN, Seminara D, Gail MH et al: Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005; 97: 715-723. (Pubitemid 40872378)
19. Altman DG, Schulz KF, Moher D et al: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694. (Pubitemid 32322245)
20. Bossuyt PM, Reitsma JB, Bruns DE et al: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-12.
21. Liberati A, Altman DG, Tetzlaff J et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
22. Vandenbroucke JP, von Elm E, Altman DG et al: Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4: e297.
23. Vandenbroucke JP: STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARKyand CONSORT: for whom does the guideline toll? J Clin Epidemiol 2009; 62: 594-596.
24. Cook NR: Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935. (Pubitemid 46294733)
25. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172. (Pubitemid 351193639)
26. Janssens ACJW, Khoury MJ: Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference? Circ Cardiovasc Genet 2010; 3: 3-5.